BioSpace News Archive

Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, is pleased to announce a research and development (R&D) strategy update, aimed at expediting its clinical program of SPL028.

Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire) will release financial results for the second quarter 2023 after the close of trading on Tuesday, August 1.

Talis Biomedical Corporation today announced that it will effect a 1-for-15 reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share (the “Reverse Stock Split”), effective at 5:00 p.m. Eastern time on July 5, 2023 (the “Effective Time”).

Spectral Medical Inc. announced the opening of three new clinical trials sites, the University of Alabama at Birmingham, Rutgers, The State University of New Jersey, and a major medical center in Wisconsin, bringing the total number of active clinical trial sites to eighteen for the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock.

Oxford BioTherapeutics announced that it has initiated a Phase 1b combination trial evaluating its lead candidate, OBT076 - a CD205 targeting ADC - and Agenus’ proprietary anti-PD1 checkpoint inhibitor, balstilimab, in patients with advanced solid tumors by dosing its first patient at a European site.

Medimaps Group, a Swiss/Global med-tech company specializing in image-processing software for assessing bone health, announced the publication of an expert paper in Osteoporosis International.

Immuron Limited, an Australian based and globally integrated biopharmaceutical company is pleased to announce FY23 sales results of its over-the-counter gastrointestinal and digestive health immune supplement Travelan® and Protectyn®.

RVL Pharmaceuticals plc, a specialty pharmaceutical company organized in Ireland focused on the commercialization of UPNEEQ®, 0.1%, for the treatment of acquired blepharoptosis, or droopy or low-lying eyelids, in adults, announced that, as authorized by the Board of Directors, the Company has been considering certain strategic alternatives.

CAMP4 Therapeutics, a biotechnology company harnessing the power of regulatory RNA to restore healthy gene expression, announced research published by the lab of co-founder Richard Young, Ph.D., in the journal Molecular Cell showing that transcription factors (TFs) interact with non-coding RNA to finely tune the regulation of gene expression.

Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that Mr. Peter Rands, co-founder, Chief Innovation & Intellectual Property Officer and former Chief Executive Officer of the Company, has left his positions as an executive officer and director of the Company and its subsidiaries, effective as of July 1, 2023.